Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
Lineage Cell Therapeutics Inc (AMEX: LCTX) closed the day trading at $0.50 down -3.85% from the previous closing price of $0.52. In other words, the price has decreased by -$3.85 from its previous closing price. On the day, 2.85 million shares were traded. LCTX stock price reached its highest trading level at $0.5262 during the session, while it also had its lowest trading level at $0.4955.
Ratios:
For a better understanding of LCTX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.65 and its Current Ratio is at 3.65. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Craig Hallum on August 20, 2024, initiated with a Buy rating and assigned the stock a target price of $4.
On November 02, 2022, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $5.
On June 14, 2022, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $4.B. Riley Securities initiated its Buy rating on June 14, 2022, with a $4 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 27 ’25 when BROADWOOD PARTNERS, L.P. bought 7,894,737 shares for $0.76 per share. The transaction valued at 6,000,000 led to the insider holds 49,560,992 shares of the business.
Howe Jill Ann bought 15,000 shares of LCTX for $8,850 on Nov 26 ’24. The Chief Financial Officer now owns 25,500 shares after completing the transaction at $0.59 per share. On Nov 26 ’24, another insider, Samuel George A. III, who serves as the General Counsel of the company, bought 15,000 shares for $0.60 each. As a result, the insider paid 9,000 and bolstered with 22,184 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LCTX now has a Market Capitalization of 114178000 and an Enterprise Value of 67518144. For the stock, the TTM Price-to-Sale (P/S) ratio is 12.02 while its Price-to-Book (P/B) ratio in mrq is 1.41. Its current Enterprise Value per Revenue stands at 7.108 whereas that against EBITDA is -3.235.
Stock Price History:
The Beta on a monthly basis for LCTX is 1.27, which has changed by -0.58677685 over the last 52 weeks, in comparison to a change of 0.09589827 over the same period for the S&P500. Over the past 52 weeks, LCTX has reached a high of $1.61, while it has fallen to a 52-week low of $0.48. The 50-Day Moving Average of the stock is -17.27%, while the 200-Day Moving Average is calculated to be -36.47%.
Shares Statistics:
Over the past 3-months, LCTX traded about 1.77M shares per day on average, while over the past 10 days, LCTX traded about 1675130 shares per day. A total of 228.36M shares are outstanding, with a floating share count of 227.36M. Insiders hold about 0.44% of the company’s shares, while institutions hold 51.09% stake in the company. Shares short for LCTX as of 1740700800 were 22027996 with a Short Ratio of 12.45, compared to 1738281600 on 21298495. Therefore, it implies a Short% of Shares Outstanding of 22027996 and a Short% of Float of 15.290000000000001.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
